We use cookies to enhance the usability of our website. If you continue, we'll assume that you are happy to receive all cookies. More information. Don't show this again.
The Survival Scatter plot shows the clinical status (i.e. dead or alive) for all individuals in the patient cohort, based on the same data that underlies the corresponding Kaplan-Meier plots. Patients that are alive at last time for follow-up are shown in blue and patients who have died during the study are shown in red.
The x-axis shows the expression levels (FPKM) of the investigated gene in the tumor tissue at the time of diagnosis. The y-axis shows the follow-up time after diagnosis (years). Both axes are complimented with kernel density curves demonstrating the data density over the axes. The top density plot shows the expression levels (FPKM) distribution among dead (red) and alive patients (blue). The right density plot shows the data density of the survived years of dead patients with high and low expression levels respectively, stratified using the cutoff indicated by the vertical dashed line through the Survival Scatter plot. This cutoff is automatically defined based on the FPKM cutoff that minimizes the p-score. The cutoff can be changed by dragging the vertical line or by entering a cutoff value in the square labeled "Current cut-off".
Under the Survival Scatter plot the p-score landscape (black curve; left axis) is shown together with dead median separation (red curve; right axis). Dead median separation is the difference in median mRNA expression between patients who have died with high and low expression, respectively. It is calculated as follows: median FPKM expression of dead patients with high expression - median FPKM expression of dead patients with low expression. This is intended to aid the user in visually exploring custom cutoffs and the associated p-scores and dead median separation.
Individual patient data is displayed and can be filtered by clicking on one or more of the category buttons on the top of the page. Categories describing expression level and patient information include: high, low, alive, dead, female, male and tumor stages. The scale of the x-axis can be toggled between linear and log-scale by clicking on the "x log" button. Mouse-over function shows TCGA ID, patient information and mRNA expression (FPKM) for each patient.
& Survival analysisi
Kaplan-Meier plots summarize results from analysis of correlation between mRNA expression level and patient survival. Patients were divided based on level of expression into one of the two groups "low" (under cut off) or "high" (over cut off). X-axis shows time for survival (years) and y-axis shows the probability of survival, where 1.0 corresponds to 100 percent.
DYNLL2 is not prognostic in Glioblastoma Multiforme (TCGA)
Stage:
Survival analysis
Current cut offi
Current cut-off shows the cut-off (FPKM) currently selected. It may be changed manually. When the current cut-off is changed, the vertical dashed line indicating cut-off, the interactive survival scatter plot and the Kaplan-Meier curve will be automatically adjusted to show results accordingly.
:
Best expression cut offi
Based on the FPKM value of each gene, patients were classified into two groups and association between prognosis (survival) and gene expression (FPKM) was examined. The best expression cut-off refers the FPKM value that yields maximal difference with regard to survival between the two groups at the lowest log-rank P-value. Best expression cut-off was selected based on survival analysis .
When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the best expression cut-off.
Median expression refers to the median FPKM value calculated based on the gene expression (FPKM) data from all patients in this dataset. When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the median expression.
Median follow up time refers to the median time (years) after diagnosis with this type of cancer, based on clinical data from all patients in this dataset.
: N/A
P scorei
Log-rank P value for Kaplan-Meier plot showing results from analysis of correlation between mRNA expression level and patient survival.
N/A
3-year survival highi
5-year survival for patients with higher expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
N/A
3-year survival lowi
5-year survival for patients with lower expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
N/A
TCGA RNA samplesi
RNA-seq data is reported as average FPKM (number Fragments Per Kilobase of exon per Million reads), generated by the The Cancer Genome Atlas (TCGA) .
Normal distribution across the dataset is visualized with box plots, shown as median and 25th and 75th percentiles. Points are displayed as outliers if they are above or below 1.5 times the interquartile range. FPKM values of the individual samples are presented next to the box plot.
Average TPM
33.6
Number of samples
141
Samples
Sample
Description
TPM
TCGA-16-0846-01A
0 years, male, white, stage:'--, dead, 119 days
72.9
TCGA-06-1804-01A
0 years, female, white, stage:'--, dead, 414 days
66.0
TCGA-32-1970-01A
0 years, male, white, stage:'--, dead, 468 days
61.1
TCGA-08-0386-01A
0 years, male, white, stage:'--, dead, 548 days
59.6
TCGA-19-5960-01A
0 years, male, white, stage:'--, dead, 455 days
59.1
TCGA-15-1444-01A
0 years, male, white, stage:'--, dead, 1537 days
58.8
TCGA-28-2514-01A
0 years, male, asian, stage:'--, alive, 160 days
58.4
TCGA-14-1034-01A
0 years, female, stage:'--, dead, 485 days
57.9
TCGA-19-1390-01A
0 years, female, white, stage:'--, dead, 772 days
57.6
TCGA-28-5215-01A
0 years, female, white, stage:'--, dead, 335 days
57.6
TCGA-76-4925-01A
0 years, male, white, stage:'--, dead, 146 days
55.6
TCGA-26-5135-01A
0 years, female, white, stage:'--, dead, 270 days
52.9
TCGA-19-2624-01A
0 years, male, white, stage:'--, dead, 5 days
52.8
TCGA-76-4929-01A
0 years, female, white, stage:'--, dead, 111 days
52.2
TCGA-02-0047-01A
0 years, male, white, stage:'--, dead, 448 days
51.8
TCGA-06-0129-01A
0 years, male, asian, stage:'--, dead, 1024 days
51.2
TCGA-27-1830-01A
0 years, male, white, stage:'--, dead, 154 days
50.7
TCGA-06-0878-01A
0 years, male, white, stage:'--, alive, 218 days
49.3
TCGA-27-2519-01A
0 years, male, white, stage:'--, dead, 550 days
49.3
TCGA-27-1834-01A
0 years, male, white, stage:'--, dead, 1233 days
48.7
TCGA-14-1825-01A
0 years, male, white, stage:'--, dead, 232 days
48.5
TCGA-06-5408-01A
0 years, female, white, stage:'--, dead, 357 days
48.4
TCGA-28-5207-01A
0 years, male, white, stage:'--, dead, 343 days
48.3
TCGA-12-0619-01A
0 years, male, white, stage:'--, dead, 1062 days
48.3
TCGA-41-5651-01A
0 years, female, black or african american, stage:'--, dead, 460 days
47.4
TCGA-12-0618-01A
0 years, male, white, stage:'--, dead, 395 days
46.5
TCGA-41-4097-01A
0 years, female, white, stage:'--, dead, 6 days
46.3
TCGA-19-2629-01A
0 years, male, white, stage:'--, dead, 737 days
46.1
TCGA-06-2570-01A
0 years, female, white, stage:'--, alive, 958 days
46.0
TCGA-26-1442-01A
0 years, male, white, stage:'--, alive, 953 days
45.4
TCGA-32-2634-01A
0 years, male, white, stage:'--, alive, 693 days
45.0
TCGA-06-0158-01A
0 years, male, white, stage:'--, dead, 329 days
44.8
TCGA-28-1753-01A
0 years, male, white, stage:'--, alive, 37 days
44.8
TCGA-06-0174-01A
0 years, male, white, stage:'--, dead, 98 days
44.7
TCGA-06-5856-01A
0 years, male, white, stage:'--, dead, 114 days
44.7
TCGA-06-2558-01A
0 years, female, white, stage:'--, dead, 380 days
44.2
TCGA-28-5216-01A
0 years, male, white, stage:'--, alive, 415 days
43.6
TCGA-06-2564-01A
0 years, male, white, stage:'--, alive, 181 days
43.2
TCGA-19-2619-01A
0 years, female, black or african american, stage:'--, alive, 294 days
43.0
TCGA-76-4931-01A
0 years, female, white, stage:'--, dead, 279 days
42.8
TCGA-06-2557-01A
0 years, male, black or african american, stage:'--, dead, 33 days
42.7
TCGA-06-0157-01A
0 years, female, white, stage:'--, dead, 97 days
42.2
TCGA-06-5411-01A
0 years, male, white, stage:'--, dead, 254 days
42.0
TCGA-27-1835-01A
0 years, female, white, stage:'--, dead, 648 days
41.7
TCGA-06-0882-01A
0 years, male, white, stage:'--, dead, 632 days
41.7
TCGA-06-2561-01A
0 years, female, white, stage:'--, dead, 537 days
41.1
TCGA-02-2483-01A
0 years, male, asian, stage:'--, alive, 466 days
40.6
TCGA-27-2523-01A
0 years, male, white, stage:'--, dead, 489 days
40.5
TCGA-12-0821-01A
0 years, male, white, stage:'--, dead, 323 days
40.5
TCGA-76-4927-01A
0 years, male, white, stage:'--, dead, 535 days
40.4
TCGA-27-1837-01A
0 years, male, white, stage:'--, dead, 427 days
39.9
TCGA-02-2485-01A
0 years, male, black or african american, stage:'--, alive, 470 days
39.6
TCGA-14-0787-01A
0 years, male, asian, stage:'--, dead, 68 days
39.0
TCGA-06-5858-01A
0 years, female, white, stage:'--, alive, 187 days
39.0
TCGA-06-0646-01A
0 years, male, white, stage:'--, dead, 175 days
38.9
TCGA-06-0686-01A
0 years, male, white, stage:'--, dead, 432 days
38.6
TCGA-32-1980-01A
0 years, male, white, stage:'--, dead, 36 days
38.5
TCGA-06-5859-01A
0 years, male, white, stage:'--, alive, 139 days
38.0
TCGA-26-5133-01A
0 years, male, white, stage:'--, alive, 452 days
37.0
TCGA-41-2571-01A
0 years, male, white, stage:'--, dead, 26 days
37.0
TCGA-06-0747-01A
0 years, male, white, stage:'--, dead, 82 days
37.0
TCGA-06-2567-01A
0 years, male, white, stage:'--, dead, 133 days
36.9
TCGA-26-5139-01A
0 years, female, white, stage:'--, alive, 48 days
36.5
TCGA-15-0742-01A
0 years, male, white, stage:'--, dead, 419 days
36.1
TCGA-32-2616-01A
0 years, female, white, stage:'--, dead, 224 days
36.0
TCGA-06-5416-01A
0 years, female, white, stage:'--, alive, 204 days
35.5
TCGA-06-2559-01A
0 years, male, white, stage:'--, dead, 150 days
35.2
TCGA-19-2620-01A
0 years, male, white, stage:'--, dead, 148 days
34.7
TCGA-06-5414-01A
0 years, male, white, stage:'--, alive, 273 days
34.0
TCGA-28-5209-01A
0 years, female, white, stage:'--, alive, 442 days
33.8
TCGA-14-0789-01A
0 years, male, white, stage:'--, dead, 342 days
33.0
TCGA-06-0211-01A
0 years, male, white, stage:'--, dead, 360 days
32.8
TCGA-06-0125-01A
0 years, female, white, stage:'--, dead, 1448 days
32.7
TCGA-26-5132-01A
0 years, male, white, stage:'--, alive, 286 days
32.7
TCGA-06-0187-01A
0 years, male, white, stage:'--, dead, 828 days
32.2
TCGA-27-2528-01A
0 years, male, white, stage:'--, dead, 480 days
31.9
TCGA-06-5417-01A
0 years, female, white, stage:'--, alive, 155 days
31.6
TCGA-76-4932-01A
0 years, female, white, stage:'--, dead, 1458 days
31.4
TCGA-06-2565-01A
0 years, male, asian, stage:'--, dead, 506 days
31.0
TCGA-41-3915-01A
0 years, male, white, stage:'--, dead, 360 days
30.9
TCGA-32-2638-01A
0 years, male, white, stage:'--, dead, 766 days
30.6
TCGA-06-0238-01A
0 years, male, white, stage:'--, dead, 405 days
30.6
TCGA-06-5413-01A
0 years, male, white, stage:'--, alive, 268 days
30.5
TCGA-06-2562-01A
0 years, male, white, stage:'--, dead, 382 days
29.9
TCGA-28-5208-01A
0 years, male, white, stage:'--, dead, 544 days
29.6
TCGA-06-0744-01A
0 years, male, white, stage:'--, dead, 1426 days
29.2
TCGA-12-3650-01A
0 years, male, white, stage:'--, dead, 333 days
28.7
TCGA-02-2486-01A
0 years, male, white, stage:'--, dead, 618 days
28.3
TCGA-32-2632-01A
0 years, male, white, stage:'--, dead, 269 days
27.8
TCGA-06-5412-01A
0 years, female, white, stage:'--, dead, 138 days
27.7
TCGA-28-5220-01A
0 years, male, white, stage:'--, dead, 388 days
27.7
TCGA-12-0616-01A
0 years, female, white, stage:'--, dead, 448 days
27.6
TCGA-06-0743-01A
0 years, male, white, stage:'--, dead, 803 days
27.4
TCGA-19-2625-01A
0 years, female, white, stage:'--, dead, 124 days
26.3
TCGA-06-0645-01A
0 years, female, white, stage:'--, dead, 175 days
26.0
TCGA-06-0168-01A
0 years, female, white, stage:'--, dead, 598 days
25.4
TCGA-06-2563-01A
0 years, female, white, stage:'--, alive, 932 days
25.4
TCGA-06-0156-01A
0 years, male, white, stage:'--, dead, 178 days
25.3
TCGA-06-0749-01A
0 years, male, black or african american, stage:'--, dead, 82 days
24.9
TCGA-06-5410-01A
0 years, female, white, stage:'--, dead, 108 days
24.9
TCGA-28-5204-01A
0 years, male, white, stage:'--, dead, 454 days
24.6
TCGA-06-0750-01A
0 years, male, white, stage:'--, dead, 28 days
24.5
TCGA-12-5299-01A
0 years, female, white, stage:'--, dead, 98 days
24.3
TCGA-41-2572-01A
0 years, male, white, stage:'--, dead, 406 days
24.1
TCGA-27-2521-01A
0 years, male, white, stage:'--, dead, 510 days
24.0
TCGA-27-1832-01A
0 years, female, white, stage:'--, dead, 300 days
22.8
TCGA-06-0190-01A
0 years, male, white, stage:'--, dead, 317 days
22.6
TCGA-06-0132-01A
0 years, male, white, stage:'--, dead, 771 days
22.4
TCGA-06-5418-01A
0 years, female, white, stage:'--, dead, 83 days
22.3
TCGA-06-0210-01A
0 years, female, white, stage:'--, dead, 225 days
21.8
TCGA-28-2513-01A
0 years, female, white, stage:'--, alive, 222 days
21.8
TCGA-12-3653-01A
0 years, female, white, stage:'--, dead, 442 days
20.8
TCGA-19-4065-01A
0 years, male, white, stage:'--, alive, 214 days
20.2
TCGA-06-0141-01A
0 years, male, white, stage:'--, dead, 313 days
20.2
TCGA-28-2509-01A
0 years, female, white, stage:'--, alive, 145 days
20.0
TCGA-06-0184-01A
0 years, male, white, stage:'--, dead, 2126 days
19.4
TCGA-32-1982-01A
0 years, female, white, stage:'--, dead, 142 days
19.3
TCGA-32-2615-01A
0 years, male, white, stage:'--, dead, 485 days
18.9
TCGA-06-0745-01A
0 years, male, white, stage:'--, dead, 239 days
18.8
TCGA-06-0644-01A
0 years, male, black or african american, stage:'--, dead, 384 days
18.7
TCGA-14-2554-01A
0 years, female, white, stage:'--, dead, 532 days
17.2
TCGA-27-2526-01A
0 years, female, white, stage:'--, dead, 87 days
17.0
TCGA-26-5134-01A
0 years, male, white, stage:'--, alive, 167 days
16.9
TCGA-14-0871-01A
0 years, female, white, stage:'--, dead, 880 days
16.4
TCGA-28-5218-01A
0 years, male, white, stage:'--, dead, 157 days
16.1
TCGA-32-4213-01A
0 years, female, white, stage:'--, alive, 604 days
15.4
TCGA-06-2569-01A
0 years, female, black or african american, stage:'--, alive, 13 days
15.2
TCGA-12-5295-01A
0 years, female, white, stage:'--, dead, 454 days
14.0
TCGA-27-2524-01A
0 years, male, white, stage:'--, dead, 231 days
13.1
TCGA-14-0817-01A
0 years, female, white, stage:'--, dead, 164 days
12.6
TCGA-32-5222-01A
0 years, male, white, stage:'--, dead, 585 days
12.6
TCGA-02-0055-01A
0 years, female, white, stage:'--, dead, 76 days
12.2
TCGA-06-0138-01A
0 years, male, white, stage:'--, dead, 737 days
12.2
TCGA-06-0130-01A
0 years, male, white, stage:'--, dead, 394 days
11.9
TCGA-14-1823-01A
0 years, female, white, stage:'--, dead, 543 days
9.1
TCGA-12-3652-01A
0 years, male, white, stage:'--, dead, 1062 days
8.4
TCGA-06-0139-01A
0 years, male, white, stage:'--, dead, 362 days
8.2
TCGA-06-0219-01A
0 years, male, white, stage:'--, dead, 22 days
7.9
TCGA-06-0178-01A
0 years, male, white, stage:'--, dead, 2681 days
7.0
TCGA-27-1831-01A
0 years, male, white, stage:'--, dead, 505 days
4.9
TCGA-14-1829-01A
0 years, male, black or african american, stage:'--, alive, 218 days
The Survival Scatter plot shows the clinical status (i.e. dead or alive) for all individuals in the patient cohort, based on the same data that underlies the corresponding Kaplan-Meier plots. Patients that are alive at last time for follow-up are shown in blue and patients who have died during the study are shown in red.
The x-axis shows the expression levels (FPKM) of the investigated gene in the tumor tissue at the time of diagnosis. The y-axis shows the follow-up time after diagnosis (years). Both axes are complimented with kernel density curves demonstrating the data density over the axes. The top density plot shows the expression levels (FPKM) distribution among dead (red) and alive patients (blue). The right density plot shows the data density of the survived years of dead patients with high and low expression levels respectively, stratified using the cutoff indicated by the vertical dashed line through the Survival Scatter plot. This cutoff is automatically defined based on the FPKM cutoff that minimizes the p-score. The cutoff can be changed by dragging the vertical line or by entering a cutoff value in the square labeled "Current cut-off".
Under the Survival Scatter plot the p-score landscape (black curve; left axis) is shown together with dead median separation (red curve; right axis). Dead median separation is the difference in median mRNA expression between patients who have died with high and low expression, respectively. It is calculated as follows: median FPKM expression of dead patients with high expression - median FPKM expression of dead patients with low expression. This is intended to aid the user in visually exploring custom cutoffs and the associated p-scores and dead median separation.
Individual patient data is displayed and can be filtered by clicking on one or more of the category buttons on the top of the page. Categories describing expression level and patient information include: high, low, alive, dead, female, male and tumor stages. The scale of the x-axis can be toggled between linear and log-scale by clicking on the "x log" button. Mouse-over function shows TCGA ID, patient information and mRNA expression (FPKM) for each patient.
& Survival analysisi
Kaplan-Meier plots summarize results from analysis of correlation between mRNA expression level and patient survival. Patients were divided based on level of expression into one of the two groups "low" (under cut off) or "high" (over cut off). X-axis shows time for survival (years) and y-axis shows the probability of survival, where 1.0 corresponds to 100 percent.
DYNLL2 is not prognostic in Glioblastoma Multiforme (validation)
Stage:
Survival analysis
Current cut offi
Current cut-off shows the cut-off (FPKM) currently selected. It may be changed manually. When the current cut-off is changed, the vertical dashed line indicating cut-off, the interactive survival scatter plot and the Kaplan-Meier curve will be automatically adjusted to show results accordingly.
:
Best expression cut offi
Based on the FPKM value of each gene, patients were classified into two groups and association between prognosis (survival) and gene expression (FPKM) was examined. The best expression cut-off refers the FPKM value that yields maximal difference with regard to survival between the two groups at the lowest log-rank P-value. Best expression cut-off was selected based on survival analysis .
When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the best expression cut-off.
Median expression refers to the median FPKM value calculated based on the gene expression (FPKM) data from all patients in this dataset. When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the median expression.
Median follow up time refers to the median time (years) after diagnosis with this type of cancer, based on clinical data from all patients in this dataset.
: N/A
P scorei
Log-rank P value for Kaplan-Meier plot showing results from analysis of correlation between mRNA expression level and patient survival.
N/A
3-year survival highi
5-year survival for patients with higher expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
N/A
3-year survival lowi
5-year survival for patients with lower expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
N/A
TCGA RNA samplesi
RNA-seq data is reported as average FPKM (number Fragments Per Kilobase of exon per Million reads), generated by the The Cancer Genome Atlas (TCGA) .
Normal distribution across the dataset is visualized with box plots, shown as median and 25th and 75th percentiles. Points are displayed as outliers if they are above or below 1.5 times the interquartile range. FPKM values of the individual samples are presented next to the box plot.
Average TPM
20.5
Number of samples
58
Samples
Sample
Description
TPM
AK079
N, NA, stage:NA, dead, 210 days
46.2
AK134
N, NA, stage:NA, dead, 360 days
36.2
AK006
N, NA, stage:NA, dead, 360 days
32.3
AK158
N, NA, stage:NA, dead, 360 days
32.0
AK002
N, NA, stage:NA, dead, 570 days
30.6
AK043
N, NA, stage:NA, alive, 660 days
30.1
AK226
N, NA, stage:NA, dead, 360 days
30.0
AK085
N, NA, stage:NA, alive, 660 days
28.6
AK149
N, NA, stage:NA, dead, 420 days
27.6
AK216
N, NA, stage:NA, dead, 360 days
27.1
AK117
N, NA, stage:NA, dead, 210 days
25.8
AK218
N, NA, stage:NA, dead, 180 days
24.7
AK088
N, NA, stage:NA, dead, 360 days
24.6
AK103
N, NA, stage:NA, alive, 1320 days
24.4
AK089
N, NA, stage:NA, dead, 330 days
24.1
AK102
N, NA, stage:NA, alive, 1740 days
23.8
AK035
N, NA, stage:NA, dead, 210 days
23.6
AK173
N, NA, stage:NA, dead, 180 days
23.4
AK081
N, NA, stage:NA, dead, 180 days
23.1
AK015
N, NA, stage:NA, alive, 720 days
23.0
AK165
N, NA, stage:NA, alive, 360 days
22.4
AK099
N, NA, stage:NA, dead, 420 days
22.3
AK167
N, NA, stage:NA, dead, 180 days
21.0
AK003
N, NA, stage:NA, dead, 600 days
21.0
AK053
N, NA, stage:NA, dead, 300 days
20.5
AK041
N, NA, stage:NA, alive, 810 days
20.4
AK124
N, NA, stage:NA, alive, 1920 days
20.0
AK100
N, NA, stage:NA, alive, 960 days
19.7
AK066
N, NA, stage:NA, alive, 960 days
19.5
AK156
N, NA, stage:NA, dead, 330 days
19.3
AK005
N, NA, stage:NA, dead, 240 days
19.0
AK195
N, NA, stage:NA, dead, 390 days
18.7
AK139
N, NA, stage:NA, dead, 270 days
18.6
AK227
N, NA, stage:NA, alive, 300 days
18.6
AK183
N, NA, stage:NA, alive, 360 days
18.5
AK231
N, NA, stage:NA, dead, 240 days
18.0
AK123
N, NA, stage:NA, dead, 180 days
17.8
AK205
N, NA, stage:NA, dead, 120 days
17.6
AK091
N, NA, stage:NA, dead, 210 days
17.2
AK142
N, NA, stage:NA, alive, 90 days
16.5
AK071
N, NA, stage:NA, dead, 540 days
16.5
AK074
N, NA, stage:NA, alive, 300 days
16.2
AK213
N, NA, stage:NA, alive, 2010 days
15.9
AK199
N, NA, stage:NA, alive, 1860 days
15.9
AK051
N, NA, stage:NA, dead, 360 days
15.8
AK055
N, NA, stage:NA, dead, 240 days
15.3
AK098
N, NA, stage:NA, dead, 660 days
15.2
AK076
N, NA, stage:NA, alive, 660 days
15.1
AK153
N, NA, stage:NA, dead, 240 days
15.1
AK188
N, NA, stage:NA, alive, 420 days
14.8
AK049
N, NA, stage:NA, dead, 180 days
13.2
AK068
N, NA, stage:NA, alive, 360 days
12.8
AK072
N, NA, stage:NA, dead, 150 days
12.4
AK178
N, NA, stage:NA, dead, 240 days
12.2
AK030
N, NA, stage:NA, dead, 120 days
12.0
AK236
N, NA, stage:NA, dead, 360 days
10.3
AK133
N, NA, stage:NA, dead, 360 days
7.7
AK185
N, NA, stage:NA, alive, 330 days
6.9
Show allShow less
GLIOBLASTOMA MULTIFORME - Protein relative expression (CPTAC)
Number of samples
110
Samples
Sample ID
Sample type
nRPX
CPT0204370003
Normal
1.6
CPT0204340003
Normal
1.5
CPT0204390003
Normal
1.5
CPT0204420003
Normal
1.5
CPT0204360003
Normal
1.5
CPT0204380003
Normal
1.4
CPT0204400003
Normal
1.4
CPT0204410003
Normal
1.3
CPT0204330003
Normal
1.3
CPT0204350003
Normal
0.8
CPT0206330003
Tumor
0.4
CPT0104220003
Tumor
0.4
CPT0206450003
Tumor
0.3
CPT0217880003
Tumor
0.3
CPT0199770003
Tumor
0.2
CPT0218770003
Tumor
0.2
CPT0087680003
Tumor
0.2
CPT0104330003
Tumor
0.2
CPT0225760003
Tumor
0.2
CPT0209440003
Tumor
0.2
CPT0190240004
Tumor
0.2
CPT0201710003
Tumor
0.2
CPT0168720003
Tumor
0.2
CPT0196850003
Tumor
0.2
CPT0064650003
Tumor
0.1
CPT0206880003
Tumor
0.1
CPT0162140003
Tumor
0.1
CPT0224330003
Tumor
0.1
CPT0221180003
Tumor
0.1
CPT0217100003
Tumor
0.1
CPT0205890003
Tumor
0.1
CPT0189250003
Tumor
0.1
CPT0218960004
Tumor
0.1
CPT0208980003
Tumor
0.0
CPT0182580003
Tumor
0.0
CPT0161730003
Tumor
0.0
CPT0182550003
Tumor
0.0
CPT0207030003
Tumor
0.0
CPT0168270003
Tumor
0.0
CPT0171580008
Tumor
0.0
CPT0218670003
Tumor
0.0
CPT0167860004
Tumor
0.0
CPT0205670004
Tumor
0.0
CPT0087730003
Tumor
0.0
CPT0189850004
Tumor
-0.1
CPT0205570003
Tumor
-0.1
CPT0071100003
Tumor
-0.1
CPT0093590003
Tumor
-0.1
CPT0125220003
Tumor
-0.1
CPT0162020003
Tumor
-0.1
CPT0206110003
Tumor
-0.1
CPT0186100003
Tumor
-0.2
CPT0207090003
Tumor
-0.2
CPT0168590003
Tumor
-0.2
CPT0093510003
Tumor
-0.2
CPT0225730003
Tumor
-0.2
CPT0189460003
Tumor
-0.2
CPT0168080003
Tumor
-0.2
CPT0125510003
Tumor
-0.2
CPT0167750004
Tumor
-0.2
CPT0217710008
Tumor
-0.2
CPT0190360004
Tumor
-0.2
CPT0218890004
Tumor
-0.2
CPT0092440003
Tumor
-0.2
CPT0168830003
Tumor
-0.2
CPT0228220003
Tumor
-0.2
CPT0189570004
Tumor
-0.2
CPT0217000004
Tumor
-0.2
CPT0224600003
Tumor
-0.2
CPT0189750004
Tumor
-0.3
CPT0087950003
Tumor
-0.3
CPT0189650004
Tumor
-0.3
CPT0087570003
Tumor
-0.3
CPT0167640003
Tumor
-0.3
CPT0123530003
Tumor
-0.3
CPT0216920008
Tumor
-0.3
CPT0206780003
Tumor
-0.3
CPT0175060003
Tumor
-0.3
CPT0162100003
Tumor
-0.3
CPT0125570003
Tumor
-0.3
CPT0217190003
Tumor
-0.3
CPT0219080004
Tumor
-0.3
CPT0182500003
Tumor
-0.3
CPT0064890003
Tumor
-0.3
CPT0093550003
Tumor
-0.3
CPT0205450004
Tumor
-0.3
CPT0205780003
Tumor
-0.3
CPT0167530003
Tumor
-0.4
CPT0206670004
Tumor
-0.4
CPT0127420003
Tumor
-0.4
CPT0078580003
Tumor
-0.4
CPT0218690004
Tumor
-0.4
CPT0168380003
Tumor
-0.4
CPT0089150003
Tumor
-0.4
CPT0167970003
Tumor
-0.4
CPT0127480003
Tumor
-0.4
CPT0218830004
Tumor
-0.4
CPT0093360003
Tumor
-0.4
CPT0224390004
Tumor
-0.5
CPT0217060003
Tumor
-0.5
CPT0093450003
Tumor
-0.5
CPT0168480003
Tumor
-0.5
CPT0079790003
Tumor
-0.5
CPT0206000004
Tumor
-0.5
CPT0224540004
Tumor
-0.6
CPT0218330004
Tumor
-0.6
CPT0002410011
Tumor
-0.6
CPT0206560003
Tumor
-0.6
CPT0217430008
Tumor
-0.7
CPT0206230003
Tumor
-0.7
Show allShow less
GLIOMA - Protein expressioni
A mouse-over function shows sample information and annotation data. Click on an image to view it in a full screen mode. Samples can be filtered based on level of antibody staining by selecting one or several of the following categories: high, medium, low and not detected. The assay and annotation is described here.
Note that samples used for immunohistochemistry by the Human Protein Atlas do not correspond to samples in the TCGA dataset.